Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Subcutaneous Trastuzumab May Offer Benefits Over Standard IV Infusion in Patients With Breast Cancer

September 26th 2012

A new formulation of trastuzumab that is administered subcutaneously appears to be as effective as the approved bodyweight-based intravenous regimen in women with HER2-positive breast cancer.

Dr. Hammond Discusses HER2 Testing Guideline Revisions

September 20th 2012

Pathologist Dr. Elizabeth Hammond, from Intermountain Healthcare, Discusses the Ongoing ASCO/CAP HER2 Testing Guideline Revisions.

Updated BOLERO-2 Data Support Efficacy of Everolimus in Breast Cancer

September 20th 2012

Updated results from the BOLERO-2 trial support the study's earlier findings that mTOR kinase inhibitor everolimus improves survival for postmenopausal patients with breast cancer.

Taking a Novel Look at an Established Agent: Malaria Drug Chloroquine Studied in a Preventive Setting for Early DCIS

September 17th 2012

In this interview, Lance A. Liotta, MD, PhD, discusses the hypothosis that led to the study and the research thus far into chloroquine.

Carrie Stricker on the Efficacy of Survivorship Care Plans

September 17th 2012

Carrie Stricker from the Abramson Cancer Center of the University of Pennsylvania on the Efficacy of Survivorship Care Plans for Posttreatment Breast Cancer Survivors.

Study Supports Role for ALND in Early Breast Cancer

September 14th 2012

Patients with early-stage breast cancer at high risk of residual nodal disease might benefit from axillary lymph node dissection.

Breast Cancer and Its Treatment May Not Cause Long-Term Fatigue

September 11th 2012

New data show that cancer-related fatigue is reported by only "a small minority" of women >6 months after completing adjuvant therapy for breast cancer.

Dr. Howard Burris Discusses the mTOR Inhibitor Everolimus

September 5th 2012

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the mTOR Inhibitor Everolimus for HER2-Negative Breast Cancer.

Dr. Gralow Discusses the Antibody Drug Conjugate T-DM1

September 4th 2012

Dr. Julie Gralow, from the Seattle Cancer Care Alliance, Discusses the Antibody Drug Conjugate T-DM1 for Breast Cancer.

Navigating Breast Cancer Survivorship: Sustaining the Good News

August 30th 2012

Forty years after the declaration of war on cancer, one of the most profound shifts in cancer care today is a new focus on treating those living beyond cancer, as well as those living with cancer.

Dr. Rugo on Antiangiogenic Therapies in Breast Cancer

August 28th 2012

Dr. Hope Rugo, from the UCSF Helen Diller Family Comprehensive Cancer Center, Examines Angiogenesis Inhibition Trials in Advanced Breast Cancer.

FDA Approval Sought for T-DM1

August 27th 2012

Genentech is seeking the FDA's approval to offer T-DM1 for patients with HER2-positive metastatic breast cancer amid updated results from the pivotal EMILIA trial showing significantly improved OS.

Dr. Louis Weiner Discusses the T-DM1 EMILIA Trial

August 27th 2012

Dr. Louis Weiner, from the Lombardi Comprehensive Cancer Center, Discusses the T-DM1 EMILIA Trial for HER2-Positive Breast Cancer.

Radiation Oncologists Often Excluded From Breast Cancer Treatment Decisions

August 23rd 2012

A "substantial minority" of radiation oncologists report that surgeons fail to include them in the breast cancer treatment decision-making process before definitive surgery.

Elaine Mardis on Sensitivity to Aromatase Inhibitors

August 20th 2012

Elaine Mardis, from the Genome Institute at Washington University School of Medicine, on Sensitivity to Aromatase Inhibitors

Combination of Anastrozole and Fulvestrant Improves Survival in Metastatic Breast Cancer

August 7th 2012

Researchers found that when anastrozole and fulvestrant are given in combination that patients with metastatic breast cancer experienced longer periods of PFS and OS.

5 PARP-Related Questions for Melinda L. Telli, MD

August 2nd 2012

Melinda L. Telli, MD, is actively involved in clinical research that focuses on DNA repair targeted therapeutics for the treatment of triple-negative and BRCA1/2 mutation-associated breast cancer.

Dr. Gralow Discusses T-DM1-Induced Thrombocytopenia

July 31st 2012

Dr. Julie Gralow from the Seattle Cancer Care Alliance Discusses T-DM1-Induced Thrombocytopenia

Putting Key Developments in Two Tumor Types in Focus

July 27th 2012

As the molecular understanding of breast cancer continues to evolve, the search for treatment targets based upon tumor subtypes and gene expression patterns is intensifying.

Lapatinib Equivalent to Trastuzumab as Neoadjuvant Therapy, but Less Effective in Metastatic Setting

July 24th 2012

Two phase III studies presented at ASCO 2012 explored the role of lapatinib in the treatment of HER2-positive breast cancer.